研究方向
心血管疾病病理机制研究
心血管疾病仍是全球范围内的头号健康杀手，而动脉血栓形成引起的心肌细胞损伤是心血管疾病发生发展的主要病理因素。虽然目前治疗心血管疾病的药物疗效肯定，但是心血管疾病的死亡率仍然非常高，说明心血管疾病发生机制有待进一步明确。我们致力于探索动脉血栓形成和心肌细胞损伤的分子机制，为完善心血管疾病发病机制提供新的理论基础，为研究传统中医药治疗心血管疾病提供理论基础和实验依据。
中西医结合干细胞研究
在“肾藏精”等中医理论的指导下，将中医基础理论与现代分子生物学技术、转基因小鼠等相结合，揭示内源性干细胞在中医药防治心脑损伤性疾病中的作用机制，并明确中医药促进干细胞移植治疗心脑损伤的作用。以中西医结合理论创新为目标，重要围绕骨髓间充质干细胞、诱导性多能干细胞和类器官开展体外药物筛选、毒性评估和替代治疗的相关基础研究及临床试验。
血小板与血栓疾病研究
血小板激活在生理性止血和病理性血栓形成中起重要作用。在急性冠状动脉综合征（ACS）、细菌感染以及糖尿病（DM）、肿瘤等不同疾病中，血小板异常激活而机制不清。我们利用蛋白组学技术，基因组学技术，与附属医院心内科，内分泌科，感染科，肾内科，重症科等多个科室展开积极合作，获取、储存、管理、分析本医院心血管疾病相关研究样本，探索血小板高反应性的分子机制。通过临床大数据进行精准医学分析，评价不同抗血小板药物的治疗预后标志物。开展心血管病流行病学调查与研究，监测与分析我国人民心脑血管病发病率和死亡率、危险因素流行和发展趋势，为国民心血管健康风险评估提供精准医学支持。
心脑血管疾病药效学评价
综合运用生命科学新的理论和技术，系统地构建与国际接轨的药物筛选方法，药效学评价模型和评价标准，建立系统规范的、与国际接轨的新药创制专业技术服务体系。围绕心衰，心肌纤维化，动脉血栓性疾病，静脉血栓性疾病，动脉粥样硬化，高血脂症，高血压、脑卒中、心肌梗死和心力衰竭等多种心脑血管疾病，从细胞、组织和整体动物模型水平上，对各种中药复方及其中药单体进行筛选，作用机制探索和药效学评价。采用评价新靶点药物的多项先进实验技术，通过开展系统、严谨的药效评价，将为中医药药物在临床试验中的有效性和安全性提供充分的实验依据。作为上海市抗血小板药物研发的对外服务平台的专业技术服务系统，力争成为国家新药研究关键技术平台的重要组成部分。
Research priorities
mechanisms of cardiovascular diseases
Cardiovascular diseases remain the first killer in the world. Arterial thrombus formation and myocardial injury are the key pathological mechanisms in cardiovascular diseases. Though current drugs are proven to be beneficial in coronary heart disease, morbidity and mortality are still high. Thus, the mechanisms of coronary heart disease need to be further investigated. Our team aims to discover novel mechanisms of arterial thrombus formation and myocardial injury. Our work will provide important new knowledge in cardiovascular diseases, and support the traditional chinese medicine on cardiovascular diseases treatment.
Stem cell research of integrated medicine
Under the guidance of traditional Chinese medicine theories "kidney storing essence", the stem cell research platform of integrated medicine combines the basic theory of traditional Chinese medicine with molecular biology technology and transgenic technique to reveal the mechanism of endogenous stem cells in prevention and treatment of cardiovascular and cerebrovascular diseases, and clarify the role of traditional Chinese medicine in promoting stem cell transplantation after cardiovascular and cerebrovascular injury. We screen the novel candidate chemicals and evaluate toxicity and alternative treatment using bone marrow mesenchymal stem cells, induced pluripotent stem cells and organoids to discover the novel protective mechanisms of traditional chinese medicine.
Platelet activation in thrombosis
Platelets play an important role in thrombosis and heamostastis. Platelets are abnormal activated in patients with acute coronary syndrome (ACS), bacterial infection, diabetes mellitus (DM) and tumor. Using proteomics and genomics technology, we cooperate with different departments of the affiliated hospital to establish biological sample bank and evaluate the mechanisms and pathological basis of abnormal platelet function and thrombosis. We also evaluate the candidate biomarker for platelet activation in different diseases, and monitor the incidence of cardiovascular and cerebrovascular events, the prevalence and risk factors. Our work will provide accurate medical evidence for cardiovascular disease assessment in China.
Pharmacology evaluation for cardiovascular diseases
We establish screening methods, pharmacodynamic animal models and evaluation standards for cardiovascular candidate chemicals, and establish a systematic and standardized technique for new drug evaluation according to standards in the world. We use in vitro cell experiments to screen the various traditional chinese medicine formula and traditional chinese medicine compounds targeting heart failure, myocardial fibrosis, arterial thrombotic diseases, venous thrombotic diseases, atherosclerosis, hyperlipidemia, hypertension, stroke, myocardial infarction, heart failure and other cardiovascular and cerebrovascular diseases. We also evaluate the underlying mechanisms and pharmacology of candidate chemicals in different animal models. Our work tries to demonstrate the effectiveness and safety of traditional Chinese medicine in clinical. As a platform for antiplatelet drug research and development, our work is an important part of technology platform for new drug research in Shanghai.